Cargando…

Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells

Clinical treatment for colorectal cancer (CRC) thus far encounters a huge challenge due to oxaliplatin-resistance. As crucial rate-limiting enzymes in aerobic glycolysis and glutaminolysis, pyruvate kinase M2 type (PKM2) and kidney-type glutaminase (GLS1) are proposed to carry important implications...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Wei-Qun, Hu, Ying-Ying, Lin, Xiao-Ping, Fan, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546471/ https://www.ncbi.nlm.nih.gov/pubmed/28498807 http://dx.doi.org/10.18632/oncotarget.17396

Ejemplares similares

Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in colorectal cancer
por: Yin, Chenxi, et al.
Publicado: (2020)

Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2
por: Sun, Wei, et al.
Publicado: (2021)

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2020)

Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis
por: Wu, Haili, et al.
Publicado: (2022)

PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines
por: Ginés, Alba, et al.
Publicado: (2015)

Gambogic acid reverses oxaliplatin resistance in colorectal cancer by increasing intracellular platinum levels
por: Wang, Qiang, et al.
Publicado: (2018)

Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer
por: Saha, Subbroto Kumar, et al.
Publicado: (2019)

Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells
por: Lin, Yanzhu, et al.
Publicado: (2019)

Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells
por: Szeliga, Monika, et al.
Publicado: (2013)

The Effect of Compound Sophora on Fluorouracil and Oxaliplatin Resistance in Colorectal Cancer Cells
por: Yin, WeiHua, et al.
Publicado: (2019)

PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma
por: Martin, Sean P., et al.
Publicado: (2020)

Knockdown of PKM2 Suppresses Tumor Growth and Invasion in Lung Adenocarcinoma
por: Sun, Hong, et al.
Publicado: (2015)

Knockdown of KLK11 reverses oxaliplatin resistance by inhibiting proliferation and activating apoptosis via suppressing the PI3K/AKT signal pathway in colorectal cancer cell
por: Zhang, Yiyi, et al.
Publicado: (2018)

Targeting REV7 effectively reverses 5-FU and oxaliplatin resistance in colorectal cancer
por: Sun, Xianjun, et al.
Publicado: (2020)

GLS2 shapes ferroptosis in hepatocellular carcinoma
por: Suzuki, Sawako, et al.
Publicado: (2023)

Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism
por: Chen, Ping, et al.
Publicado: (2021)

Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer
por: Xu, Zongbin, et al.
Publicado: (2016)

Tanshinone IIA Reverses Oxaliplatin Resistance In Human Colorectal Cancer Via Inhibition Of ERK/Akt Signaling Pathway
por: Zhang, Yonggang, et al.
Publicado: (2019)

MiR-29b reverses oxaliplatin-resistance in colorectal cancer by targeting SIRT1
por: Liu, Hui, et al.
Publicado: (2018)

PKMζ knockdown disrupts post-ischemic long-term potentiation via inhibiting postsynaptic expression of aminomethyl phosphonic acid receptors
por: Cheng, Nan, et al.
Publicado: (2015)

Knockdown of long non-coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells
por: Fan, Heng, et al.
Publicado: (2018)

Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro
por: Zhao, Qun, et al.
Publicado: (2010)

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer
por: Hsieh, Chi-Che, et al.
Publicado: (2022)

Regulation of Cardiac Fibroblast GLS1 Expression by Scleraxis
por: Chattopadhyaya, Sikta, et al.
Publicado: (2022)

GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights
por: Zhang, Danfeng, et al.
Publicado: (2023)

CAC1 knockdown reverses drug resistance through the downregulation of P-gp and MRP-1 expression in colorectal cancer
por: Chen, Nanzheng, et al.
Publicado: (2019)

MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy
por: Ren, Wei-Wei, et al.
Publicado: (2018)

The Role of Cyanidin-3-O-glucoside in Modulating Oxaliplatin Resistance by Reversing Mesenchymal Phenotype in Colorectal Cancer
por: Kurter, Hasan, et al.
Publicado: (2023)

Activation of Akt protects cancer cells from growth inhibition induced by PKM2 knockdown
por: Qin, Xiaodong, et al.
Publicado: (2014)

Emerging roles of non-coding RNAs in colorectal cancer oxaliplatin resistance and liquid biopsy potential
por: Luo, Zheng-Dong, et al.
Publicado: (2023)

Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer
por: Yan, Shi-Hai, et al.
Publicado: (2022)

Correction to: MicroRNA-125b reverses oxaliplatin resistance in hepatocellular carcinoma by negatively regulating EVA1A mediated autophagy
por: Ren, Wei-Wei, et al.
Publicado: (2018)

LRH‐1 activation alleviates diabetes‐induced podocyte injury by promoting GLS2‐mediated glutaminolysis
por: Hu, Jijia, et al.
Publicado: (2023)

FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression
por: Tong, Jiafeng, et al.
Publicado: (2019)

Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer
por: Zhang, Junfeng, et al.
Publicado: (2019)

Zuo Jin Wan Reverses the Resistance of Colorectal Cancer to Oxaliplatin by Regulating the MALAT1/miR-200s/JNK Signaling Pathway
por: Wei, Zhenzhen, et al.
Publicado: (2022)

Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer
por: Chocry, Mathieu, et al.
Publicado: (2022)

Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer
por: Yu, Zhaoliang, et al.
Publicado: (2021)

Identification of GLS as a cuproptosis-related diagnosis gene in acute myocardial infarction
por: Liu, Zheng, et al.
Publicado: (2022)

Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma
por: Fu, Xiu-Tao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sv9ig8g74pnq5nn3482s2ljjrd